SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Livi R, Teghini L, Pignone A, Generini S, Matucci-Cerinic M, Cagnoni M. Renal functional reserve is impaired in patients with systemic sclerosis without clinical signs of kidney involvement. Ann Rheum Dis 2002; 61: 6826.
  • 2
    Rivolta R, Mascagni B, Berruti V, Quarto Di Palo F, Elli A, Scorza R, et al. Renal vascular damage in systemic sclerosis patients without clinical evidence of nephropathy. Arthritis Rheum 1996; 39: 10304.
  • 3
    Clements PJ, Lachenbruch PA, Furst DE, Maxwell M, Danovitch G, Paulus HE. Abnormalities of renal physiology in systemic sclerosis: a prospective study with 10-year followup. Arthritis Rheum 1994; 37: 6774.
  • 4
    Kovalchik MT, Guggenheim SJ, Silverman MH, Robertson JS, Steigerwald JC. The kidney in progressive systemic sclerosis: a prospective study. Ann Intern Med 1978; 89: 8817.
  • 5
    Steen VD, Medsger TA. Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum 2000; 43: 243744.
  • 6
    Medsger TA Jr, Rodnan GP, Robinson H. Survival with systemic sclerosis: a lifetable analysis of clinical and demographic factors in 309 patients. Ann Intern Med 1971; 75: 36975.
  • 7
    Steen VD, Medsger TA. Long-term outcomes of scleroderma renal crisis. Ann Intern Med 2000; 133: 6003.
  • 8
    Steen VD, Powell DL, Medsger TA. Clinical correlations and prognosis based on serum autoantibodies in patients with systemic sclerosis. Arthritis Rheum 1988; 31: 196203.
  • 9
    Steen VD, Costantino JP, Shapiro AP, Medsger TA. Outcome of renal crisis in systemic sclerosis: relation to availability of angiotensin converting enzyme (ACE) inhibitors. Ann Intern Med 1990; 113: 3527.
  • 10
    Rubin LJ, Badesch DB, Barst RJ, Nazzareno N, Black CM, Keogh A, et al, Bosentan Randomized Trial of Endothelin Antagonist Therapy Study Group. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002; 346: 896903.
  • 11
    Badesch DB, Tapson VF, McGoon MD, Brundage BH, Rubin LJ, Wigley FM, et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease: a randomized, controlled trial. Ann Intern Med 2000; 132: 42534.
  • 12
    Simonneau G, Barst RJ, Galie N, Naeije R, Rich S, Bourge RC, et al, Treprostinil Study Group. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 2002; 165: 8004.
  • 13
    MacLean MR. Endothelin-1: a mediator of pulmonary hypertension? Pulm Pharmacol Ther 1998; 11: 12532.
  • 14
    Bouros D, Wells AU, Nicholson AG, Colby TV, Polychronopoulos V, Pantelidis, et al. Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. Am J Respir Crit Care Med 2002; 165: 15816.
  • 15
    White B, Moore WC, Wigley FM, Xiao HQ, Wise RA. Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis. Ann Intern Med 2000; 132: 94754.
  • 16
    Wells AU, Cullinan P, Hansell DM, Rubens MB, Black CM, Newman-Taylor AJ, et al. Fibrosing alveolitis associated with systemic sclerosis has a better prognosis than lone cryptogenic fibrosing alveolitis. Am J Respir Crit Care Med 1994; 149: 158390.
  • 17
    Wells AU, Hansell DM, Rubens MB, Cailes JB, Black CM, du Bois RM. Functional impairment in lone cryptogenic fibrosing alveolitis and fibrosing alveolitis associated with systemic sclerosis: a comparison. Am J Respir Crit Care Med 1997; 156: 165764.
  • 18
    Wells AU, Hansell DM, Haslam PL, Rubens MB, Cailes J, Black CM, et al. Bronchoalveolar lavage cellularity: lone cryptogenic fibrosing alveolitis compared with the fibrosing alveolitis of systemic sclerosis. Am J Respir Crit Care Med 1998; 157: 147482.
  • 19
    Witt C, Borges AC, John M, Fietze I, Baumann G, Krause A. Pulmonary involvement in diffuse cutaneous systemic sclerosis: broncheoalveolar fluid granulocytosis predicts progression of fibrosing alveolitis. Ann Rheum Dis 1999; 58: 63540.
  • 20
    Daniil ZD, Gilchrist FC, Nicholson AG, Hansell DM, Harris J, Colby TV, du Bois RM. A histologic pattern of nonspecific interstitial pneumonia is associated with a better prognosis than usual interstitial pneumonia in patients with cryptogenic fibrosing alveolitis. Am J Respir Crit Care Med 1999; 160: 899905.
  • 21
    McCormick LL, Zhang Y, Tootell E, Gilliam AC. Anti-TGF-β treatment prevents skin and lung fibrosis in murine sclerodermatous graft-versus-host disease: a model for human scleroderma. J Immunol 1999; 163: 56939.
  • 22
    Kahari VM, Sandberg M, Kalimo H, Vuorio T, Vuorio E. Identification of fibroblasts responsible for increased collagen production in localized scleroderma by in situ hybridization. J Invest Dermatol 1988; 90: 66470.